Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Trial Status:  Active
Results 1-25 of 320 for your search:
Start Over
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-4407, B1771009, NCT00700258
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO200801, NCT00777504
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001LIC01, NCT01206764
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K5-4406, B1771015, NCT01210482
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 327/10, NCT01402089
The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: No age specified
Sponsor: Other
Protocol IDs: Dalhousieurosrs-2011, NCT01413607
Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1771016, NCT01420601
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and ove
Sponsor: Other
Protocol IDs: iOM-605, 2011-001138-40, NCT01521715
Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Phase: Phase IV
Type: Behavioral study, Biomarker/Laboratory analysis, Health services research
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2013P001036, 1R01CA166147-01A1, NCT01871506
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061075, NCT02156895
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061078, ADONIS, NCT02184416
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181213, RENACALL, NCT02187042
Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IRFMN-RCC-6691, NCT02338570
Post Marketing Surveillance for ICE-SENSE™3 a Cryotherapy Treatment of Renal Cell Carcinoma
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICMRC-01, NCT02399124
Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UROUSP - 005, NCT01809119
Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Dnr 151:2010/81099, 2008-001491-77, NCT02030717
SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181109, 2006-004024-37, S-TRAC, NCT00375674
Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SUIR8687, NCT00869011
Clinical Trial to Assess the Importance of Nephrectomy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P070144, NCT00930033
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0931, U10CA032102, NCI-2011-02028, SWOG-S0931, NCT01120249
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
Phase: Phase III
Type: Diagnostic
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0845, NCI-2011-03288, NCT01224288
Start Over